Testosterone Replacement in a Man with Intermediate-risk Prostate Cancer.

Area of Science:

• Andrology
• Urology
• Oncology

Background:

• Hypogonadism is a condition of insufficient testosterone production.
• Prostate cancer treatment can impact hormonal balance.
• Testosterone therapy (TTh) is used to manage hypogonadism.

Purpose of the Study:

• To evaluate the appropriateness of testosterone therapy (TTh) in hypogonadal men with a history of prostate cancer.
• To review the evidence supporting TTh in localized and intermediate-risk prostate cancer survivors.

Main Methods:

• Literature review of existing studies on testosterone therapy and prostate cancer.
• Analysis of evidence regarding TTh safety and efficacy in different risk categories of prostate cancer.

Main Results:

• Compelling, though not conclusive, evidence supports TTh for hypogonadal men with successfully treated localized prostate cancer, irrespective of tumor grade.
• The use of TTh in hypogonadal men with intermediate-risk prostate cancer who have not undergone primary treatment but desire androgen supplementation warrants consideration.

Conclusions:

• Testosterone therapy (TTh) is justifiable for hypogonadal men with successfully treated localized prostate cancer.
• Careful consideration and individualized assessment are necessary for hypogonadal men with intermediate-risk prostate cancer considering TTh without primary treatment.